Compare TG Therapeutics Inc (TGTX) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? TG Therapeutics Inc trades at $49.62 (market cap $7.64B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $39.44. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| TGTX | XDTE | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $59.06 | $44.76 |
52-Week Low | $26.94 | $36.00 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
